Navigation Links
Personalized Stem Cells, Inc. Announces FDA Approval of IND Application for Treatment of Osteoarthritis with Stem Cells
Date:7/23/2019

Personalized Stem Cells, Inc (“PSC”), a human adipose-derived stem cell company, has received FDA approval for a New Drug (IND) application for use of a person’s own adipose-derived stem cells to treat their osteoarthritis. The first clinical trial, expected to begin in August, uses stem cells as a treatment of osteoarthritis in the knee.

This is the first of several planned clinical trials which will enable qualified PSC-enrolled physicians to provide FDA compliant, regulated quality cell therapy to patients suffering from osteoarthritis. PSC plans to conduct a series of FDA approved clinical trials starting with uses in orthopedics and expanding to other medical conditions in the future.

PSC is working with the FDA to provide alternatives to unregulated, in-clinic stem cell processing and unapproved “regenerative” therapies. The current environment of in-office, unregulated manufacturing of stem cells by physicians has come under serious regulatory action by the FDA, FTC, and the Federation of State Medical Boards. It is clear that the only allowed use of stem cells will be through legitimate FDA clinical trials with manufacturing in a controlled FDA inspected, GMP compliant facility.

PSC was founded by Robert Harman, DVM, MPVM and Michael Dale, both of whom also co-founded VetStem Biopharma and are both experienced serial entrepreneurs.

“This first clinical trial will not only provide an approved method for treatment of knee arthritis, but it will also demonstrate that it is possible to work within the FDA regulatory guidelines to bring advanced stem cell therapy to the public. We have made remarkable progress in obtaining our first approval in less than one year after forming the company,” says Mr. Dale.

PSC has enrolled a limited number of clinical sites around the U.S. to provide treatment of knee osteoarthritis using stem cells. The physicians in this first clinical trial are among the most experienced stem cell physicians in the country. Contact PSC for clinical trial information, clinical trial site locations, or investment information.

About Personalized Stem Cells, Inc.
Personalized Stem Cells was formed in 2018 to advance and legitimize human regenerative medicine. This privately held biopharmaceutical enterprise, based near San Diego (California), offers qualified physicians who enroll, an FDA compliant autologous stem cell product (from patient’s own fat tissue) for use in FDA approved clinical trials. PSC is driving development and adoption of stem cell and regenerative medicine within the FDA-IND process by providing quality manufactured, safety tested cells, and well-defined clinical trials. PSC has licensed a portfolio of over 70 issued patents in the field of regenerative medicine.

Read the full story at https://www.prweb.com/releases/personalized_stem_cells_inc_announces_fda_approval_of_ind_application_for_treatment_of_osteoarthritis_with_stem_cells/prweb16454322.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology news :

1. Personalized Medicine: A New Approach to Treat Periodontal Diseases
2. Zipongo Incorporates 23andMe Reports Into Personalized Nutrition Plans
3. Personalized Medicine - Scientific and Commercial Aspects - 318 Companies Profiled with 575 Collaborations - Research and Markets
4. NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology
5. @USANAincs Personalized Nutrition Program Wins Industry Innovation Award
6. "Personalized Medicine in Human Space Flight" Listed Among Most Influential Papers of 2013 and 2014
7. Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers
8. Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine
9. New partnership brings more personalized cancer treatment to Philadelphia
10. Patient-specific stem cells and personalized gene therapy
11. Genealogy and biogeography meet personalized medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2020)... ... January 23, 2020 , ... ... blood cells from stem cells. The red blood cells are made utilizing ... controlled conditions, for transfusion therapy and replaces the need for a human blood ...
(Date:1/22/2020)... , ... January 21, 2020 , ... ... to lead the company’s new Business Development Department. The move, which is part ... had been previously serving as the company’s Senior Vice President where he oversaw ...
(Date:1/22/2020)... , ... January 21, 2020 ... ... in integrating cold chain operations, developing transport validation strategies, supporting global regulatory ... both Inc. 5000 and the Houston Business Journal as a fastest growing ...
Breaking Biology News(10 mins):
(Date:12/31/2019)... ... ... At this year's SLAS conference, Visikol will present several talks on the ... culture , advanced imaging and multiplex analysis . Specifically, the Visikol ... inflammation and fibrosis as well as a 2D cell culture approach for ...
(Date:12/18/2019)... ... December 17, 2019 , ... Innovative Health, ... reprocessing Electrophysiology (EP) devices since the company’s inception in 2016. This marks a ... (a Johnson & Johnson company) have received 2 and 4 EP device clearances, ...
(Date:12/4/2019)... ... December 03, 2019 , ... A new survey by MedReps ( ... CONMED as the overall best medical sales companies to work for in 2020. ... polled over 1,200 professionals from the MedReps community to identify which medical sales companies ...
(Date:12/4/2019)... CITY, S.D. (PRWEB) , ... December 04, 2019 , ... ... times smaller than a human hair, but its potential impact on the pharmaceutical industry ... Ph.D., a professor of biological and chemical engineering at South Dakota School of ...
Breaking Biology Technology: